Home > Boards > US Listed > Medical - Drugs >

Seelos Therapeutics Inc (SEEL)

SEEL RSS Feed
Add SEEL Price Alert      Hide Sticky   Hide Intro
Moderator: beambe
Search This Board: 
Last Post: 3/21/2019 2:26:50 PM - Followers: 234 - Board type: Free - Posts Today: 8

Apricus Biosciences, Inc. (APRI) 

 

 

http://www.apricusbio.com/

 

 

 

 

Company Address:

11975 El Camino Real, Suite 300
San Diego, CA 92130
T (858) 222-8041

 CIK:   0001017491

Apricus Website:    http://www.apricusbio.com/index.html

 

 
 

NexACT® - Multi-Route Drug Delivery Technology

NexACT® Multi-Route drug delivery technology facilitates compounds crossing the lipid bilayer and yet biodegrades in vivo to natural amino acids and natural fatty acids.

This technology is useful for:
  • Penetrating, proprietary, topical & transdermal formulations.
    Improving oral bioavailability of poorly soluble, poorly permeating compounds (BCS class 2-4)
    Delivering siRNA therapeutics into the cells; in vivo validated
    Development of more effective, penetrating cosmeceutic formulations
    Preservative

The safety and permeation properties of this proprietary drug delivery technology was demonstrated in the Vitaros® product which was approved for the treatment of erectile dysfunction in November 2010 by Health Canada, and approved by the European Union in June 2013.  Vitaros has been launched in all European Union countries by partner pharmaceutical companies.  Additional agreements for marketing Vitaros have been established.  For more information see the company's most recent 10K SEC filing.

In September 2015 the company anounced an agreement with Allergan to reacquire marketing rights for Vitaros in the U.S.  The company expects to resubmit a filing for FDA approval of Vitaros in the second half of 2016.  For more information see the company's most recent 10K SEC filing.


The company expects to initiate a Phase IIb clinical trial for RayVa to treat Reynaud's Syndrome in the second half of 2016.

In October 2014, the company acquired U.S. development and licensing rights to Fispemifene, a Selective Estrogen-Receptor Modulator (SERM) for treatment of secondary hypogonadism.  In March 2016 the company discontinued development Fispemifene after disappointing Phase IIb results.
.

 Filings:  http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0001017491&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Share Structure:
Outstanding Shares
 61,78M

Authorized Shares
75,000,000
  

Investor Relations:
ir@apricusbio.com
Tel: +1-858 222-8041

Matthew Beck
The Trout Group
:(646)378 2933

 

 

 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

 

Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

 


                                                                           
Image result for vitaros                                                  

Image result for vitaros

SEEL
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SEEL News: Statement of Ownership (sc 13g) 03/11/2019 09:22:30 AM
SEEL News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 03/08/2019 06:46:28 AM
SEEL News: Current Report Filing (8-k) 03/08/2019 06:40:37 AM
SEEL News: Seelos Therapeutics Announces Acquisition of an Exclusive License to Intellectual Property from The UC Regents to Potential D... 03/07/2019 08:00:00 AM
SEEL News: Seelos Therapeutics to Webcast Presentation at the 39th Annual Cowen Health Care Conference and Participate in the 31st Annua... 03/06/2019 08:00:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#29188   SEEL should bounce. IMO lvhd 03/21/19 02:26:50 PM
#29187   Looks like we'll all just have to wait Boneride 03/21/19 02:06:46 PM
#29186   Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical Goingdeep 03/21/19 12:22:43 PM
#29185   As far as what exactly?? That Ruth food4thought 03/21/19 11:39:17 AM
#29184   Kamikaze Therapeutics, Inc. Boneride 03/21/19 10:44:49 AM
#29183   Looks like shorters are having some problems right here Goingdeep 03/21/19 09:58:48 AM
#29182   Go with your gut food4thought 03/21/19 09:32:29 AM
#29181   Thanx, B-Boy. I just have a very, very, Boneride 03/21/19 03:13:25 AM
#29180   ALL STOCKS CAN DO THIS.. THIS HAS POTENTIAL.. berdboy 03/20/19 09:22:56 PM
#29179   Will this simply continue to tank until it Boneride 03/20/19 07:26:24 PM
#29178   It is reasonably clear that the shorts are Leonard McKinley 03/20/19 04:25:15 PM
#29177   This POS is going in the wrong direction. lvhd 03/20/19 12:08:26 PM
#29176   booktrader 03/19/19 10:15:56 PM
#29175   https://seekingalpha.com/article/4249883-seelos-therapeutics-looks-new-promising booktrader 03/19/19 10:15:19 PM
#29174   https://seekingalpha.com/article/4249883-seelos-therapeutics-looks-new-promising booktrader 03/19/19 10:15:02 PM
#29173   Combine that with a massive short interest (I Goingdeep 03/19/19 03:38:28 PM
#29172   Few PRs about the conference last week and aks_v 03/19/19 03:32:39 PM
#29171   Wooow, this is going up fast on huge Goingdeep 03/19/19 02:44:31 PM
#29170   Looks like it. Kabuli 03/19/19 12:48:57 PM
#29169   LOOKS LIKE A TRIPLE BOTTOM ,BOUNCED AT 2.55 berdboy 03/19/19 12:28:34 PM
#29168   Currently there are 13% shorters in SEEL. Once Goingdeep 03/19/19 11:24:20 AM
#29167   Dunno... but pre-market is already green which is Goingdeep 03/19/19 09:20:59 AM
#29166   <2.50? 0210 03/19/19 08:56:51 AM
#29165   You are still hovering over this? Kabuli 03/19/19 01:23:17 AM
#29164   Technically these moves were expected and technically today CaptStockWolf 03/18/19 10:17:45 PM
#29163   If by loading zone you mean take a food4thought 03/18/19 10:03:59 PM
#29162   This is loading zone CaptStockWolf 03/18/19 09:53:01 PM
#29161   Poor Souls DUMP this POS already cheezus!!! Been ALL-IN888 03/18/19 07:27:20 PM
#29160   That’s not necessarily news, it’s simply a company food4thought 03/18/19 05:08:48 PM
#29159   News coming tomorrow? Seelos Therapeutics is taking part Goingdeep 03/18/19 03:47:07 PM
#29158   New week for Seel. I have a feeling Goingdeep 03/18/19 09:24:21 AM
#29157   Green CBD_Kindaguy 03/15/19 04:10:51 PM
#29156   Red beambe 03/15/19 03:51:09 PM
#29155   Not being a Basher as I hold a food4thought 03/15/19 02:43:50 PM
#29154   According to TD Ameritrade feed it's set for Moeclay 03/15/19 01:15:20 PM
#29153   I always try to get the news directly Goingdeep 03/15/19 11:25:59 AM
#29152   Let's go!!!!!!!!!! CBD_Kindaguy 03/15/19 10:33:37 AM
#29151   $SEEL next $BPTH in the making.... Huge Reversal today!!! aks_v 03/15/19 10:25:03 AM
#29150   That volume and that chart speak for themselves... Goingdeep 03/15/19 10:19:53 AM
#29149   Woow, SEEL already GREEN today. Something good coming! Goingdeep 03/15/19 10:13:37 AM
#29148   Red to green. Nice lvhd 03/15/19 10:13:18 AM
#29147   "small" starter. haven't backed-up truck, lol. On 0210 03/14/19 11:51:33 PM
#29146   Is there an upcoming secondary stock offering on booktrader 03/14/19 09:10:38 PM
#29145   If this is POS, why you are here Kabuli 03/14/19 06:54:10 PM
#29144   2.65 AHS still holding this POS??? Cheezus!!! ALL-IN888 03/14/19 05:44:58 PM
#29143   Institutionals now own 101.49% of SEEL float. 0210 03/14/19 02:44:35 PM
#29142   One potential press release could be that they Goingdeep 03/14/19 02:42:02 PM
#29141   This looks like a perfect setup for a Goingdeep 03/14/19 02:27:10 PM
#29139   Technical analysis indicates that it will bounce of Goingdeep 03/14/19 01:54:15 PM
#29138   I think we have finally found bottom, at KER12 03/14/19 01:20:09 PM
PostSubject